These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 27283730)

  • 1. Ridinilazole: a novel therapy for Clostridium difficile infection.
    Vickers RJ; Tillotson G; Goldstein EJ; Citron DM; Garey KW; Wilcox MH
    Int J Antimicrob Agents; 2016 Aug; 48(2):137-43. PubMed ID: 27283730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ridinilazole for the treatment of Clostridioides difficile infection.
    Carlson TJ; Endres BT; Bassères E; Gonzales-Luna AJ; Garey KW
    Expert Opin Investig Drugs; 2019 Apr; 28(4):303-310. PubMed ID: 30767587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin.
    Thorpe CM; Kane AV; Chang J; Tai A; Vickers RJ; Snydman DR
    PLoS One; 2018; 13(8):e0199810. PubMed ID: 30071046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
    Okhuysen PC; Ramesh MS; Louie T; Kiknadze N; Torre-Cisneros J; de Oliveira CM; Van Steenkiste C; Stychneuskaya A; Garey KW; Garcia-Diaz J; Li J; Duperchy E; Chang BY; Sukbuntherng J; Montoya JG; Styles L; Clow F; James D; Dubberke ER; Wilcox M
    Clin Infect Dis; 2024 Jun; 78(6):1462-1472. PubMed ID: 38305378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.
    Snydman DR; McDermott LA; Thorpe CM; Chang J; Wick J; Walk ST; Vickers RJ
    J Antimicrob Chemother; 2018 Aug; 73(8):2078-2084. PubMed ID: 29718329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.
    Corbett D; Wise A; Birchall S; Warn P; Baines SD; Crowther G; Freeman J; Chilton CH; Vernon J; Wilcox MH; Vickers RJ
    J Antimicrob Chemother; 2015; 70(6):1751-6. PubMed ID: 25652750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.
    Vickers R; Robinson N; Best E; Echols R; Tillotson G; Wilcox M
    BMC Infect Dis; 2015 Feb; 15():91. PubMed ID: 25880933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the diagnosis and treatment of Clostridium difficile infections.
    Peng Z; Ling L; Stratton CW; Li C; Polage CR; Wu B; Tang YW
    Emerg Microbes Infect; 2018 Feb; 7(1):15. PubMed ID: 29434201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.
    Bassères E; Endres BT; Khaleduzzaman M; Miraftabi F; Alam MJ; Vickers RJ; Garey KW
    J Antimicrob Chemother; 2016 May; 71(5):1245-51. PubMed ID: 26895772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
    Vickers RJ; Tillotson GS; Nathan R; Hazan S; Pullman J; Lucasti C; Deck K; Yacyshyn B; Maliakkal B; Pesant Y; Tejura B; Roblin D; Gerding DN; Wilcox MH;
    Lancet Infect Dis; 2017 Jul; 17(7):735-744. PubMed ID: 28461207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of treatment algorithms for Clostridium difficile infection.
    Ooijevaar RE; van Beurden YH; Terveer EM; Goorhuis A; Bauer MP; Keller JJ; Mulder CJJ; Kuijper EJ
    Clin Microbiol Infect; 2018 May; 24(5):452-462. PubMed ID: 29309934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Novel DNA Binding Mechanism of Ridinilazole, a Precision
    Mason CS; Avis T; Hu C; Nagalingam N; Mudaliar M; Coward C; Begum K; Gajewski K; Alam MJ; Bassères E; Moss S; Reich S; Duperchy E; Fox KR; Garey KW; Powell DJ
    Antimicrob Agents Chemother; 2023 May; 67(5):e0156322. PubMed ID: 37093023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Navigating changes in
    Durham SH; Le P; Cassano AT
    J Manag Care Spec Pharm; 2020 Dec; 26(12-a Suppl):S3-S23. PubMed ID: 33533699
    [No Abstract]   [Full Text] [Related]  

  • 15. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
    Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
    J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile.
    Collins DA; Wu Y; Tateda K; Kim HJ; Vickers RJ; Riley TV
    J Antimicrob Chemother; 2021 Mar; 76(4):967-972. PubMed ID: 33351917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent Clostridium difficile infection: what are the treatment options?
    van Nispen tot Pannerden CM; Verbon A; Kuipers EJ
    Drugs; 2011 May; 71(7):853-68. PubMed ID: 21568363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 20. Fighting against Clostridioides difficile infection: Current medications.
    Quan M; Zhang X; Fang Q; Lv X; Wang X; Zong Z
    Int J Antimicrob Agents; 2024 Jul; 64(1):107198. PubMed ID: 38734214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.